STOCK TITAN

Gilead Sciences: National Black HIV/AIDS Awareness Day

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Argus Session date unavailable
-0.83% session move Open Argus
Details

News Market Reaction – GILD

The recorded move for GILD in the trading session of this news was -0.83%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

NORTHAMPTON, MA / ACCESSWIRE / February 29, 2024 / This year's theme for National Black HIV/AIDS Awareness Day is "Engage, Educate, Empower: Uniting to End HIV/AIDS in Black Communities." We spoke with C. Virginia Fields, President and CEO of National Black Leadership Commission on Health (Black Health), a Gilead grantee, about how together, we can take action toward meaningful change.

We commend Virginia and our many community partners for continuing to honor and advance the decades of progress that Black communities have made in HIV.

Learn more: https://gilead.inc/487PjBu

Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences



View the original press release on accesswire.com

Keep reading